DNX-2401

Does anyone have any information on the trial using DNX-2401?  We are trying to decide if the risks outweigh the benefit or vice versa. Its great for the 20% that had extended life but what they won't tell us is how those people were living. Did there side effects continue where even thought they lived three more years they were miserable? If anyone has any information to shed some light on this that would be great. Thank you!

DNX-2401 oncolytic adenovirus phase 1 trial results

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma (click here for abstract)

I've uploaded the full PDF to the Brain Tumor Library -> 1. Therapies - human studies -> DNX-2401

In group A, 5 out of 25 patients (20%) lived for at least 3 years post-injection of DNX-2401, and three of these (12%) had dramatic responses (at least 95% reduction in cross-sectional area of enhancing tumor) and at least three years of progression-free survival.

This therapy is currently being tested in combination with pembrolizumab (anti-PD-1).

https://clinicaltrials.gov/ct2/show/NCT02798406

Blood-brain barrier and immune checkpoint inhibitors

Blood-brain barrier and immune checkpoint inhibitors

My partner has a recurrent and unoperable glioblastoma.
He is considering a therapy with immune checkpoint inhibitors (e.g. pembrolizumab or atezolizumab) as his tumor has extremely high mutation burden. Some doctors are in favour but some are not convinced and say that it won't work because of blood brain barrier (BBB).
Is there any research showing immune checkpoint inhibitors don't cross BBB?

DNX-201 With Pembrolizumab (Keytruda)

Hello All,

I am looking for any comments, experience and suggestions with the DNX-2401 trial.

The Phase II just opened and I am enrolled for the procedure on Monday.

My GBM was resected in June 2015 and there has been some mass increases in the area between my cavity and skull.  Shows some signs of tumor and some signs as necrosis.


Of the couple of trial options offered to me, (southern California) these seems like the best, like the biopsy aspect of this trial.

When I asked a GBM research scientist friend of mine, I got the following comment:

Paraphased:

 - DNX-2401 is a one shot try.  If it comes back up the biopsy hole, then nothing is going to happen.

So this makes sense, that if no DNX-201 then nothing for the PD1 to work on.

But is this really a concern?

Any, why cannot you just re-inject if this happens?

Marc

DNX-2401 virotherapy plus PD1 antibody trial

Many of you probably already saw this on Al's news blast, but I wanted to post it here too:  a new phase 2 trial will be testing DNAtrix's DNX-2401 virotherapy with Merck's PD-1 antibody pembrolizumab (Keytruda).

http://www.businesswire.com/news/home/20151001005478/en/Merck-DNAtrix-Announce-Phase-2-Immuno-Oncology-Collaboration#.VhMY6vlVikp

This will be the second trial to combine a PD-1 antibody with a second immunotherapy (the other is Duke's trial combining their CMV-targeted dendritic cell vaccine with nivolumab, plus pre-conditioning of the vaccination site with tetanus/diptheria toxoid.

https://www.clinicaltrials.gov/ct2/show/NCT02529072

These are just the sorts of combinations we need!